Colorectal Cancer Treatment Options in China: Targeted Therapy, Immunotherapy and Innovative Drugs

Colorectal cancer (CRC) is one of the most common malignant tumors worldwide and remains a leading cause of cancer incidence and mortality, according to the World Health Organization and the National Cancer Institute.

In recent years, advances in oncology research have significantly expanded colorectal cancer treatment options. A growing number of therapies have been approved and introduced into clinical practice in China, including traditional chemotherapy, targeted therapy, and immunotherapy.

These treatments include well-established medicines developed by international pharmaceutical companies as well as innovative drugs developed by Chinese biotechnology firms. Together, they provide patients with more diverse and personalized colorectal cancer treatment strategies.

✨ As part of China’s pharmaceutical supply chain, China pharmaceutical wholesaler DengYueMed continues to monitor global developments in oncology therapies and promotes information exchange and collaboration related to cancer, rare disease, and chronic disease medications.

This article provides an overview of commonly used colorectal cancer treatment options in China in 2026, including chemotherapy drugs, targeted therapies, immunotherapies, and several innovative Chinese medicines, helping readers better understand the current landscape of colorectal cancer drug treatment.

Overview of Colorectal Cancer Treatment

Colorectal cancer includes both colon cancer and rectal cancer, and treatment strategies are typically determined by several factors:

• Tumor stage
• Molecular characteristics
• Patient health condition

The most common colorectal cancer treatment options include:

• Surgery
• Chemotherapy
• Targeted therapy
• Immunotherapy

For early-stage colorectal cancer, surgery remains the primary treatment option. However, for advanced or metastatic colorectal cancer, systemic treatments such as chemotherapy, targeted therapy, and immunotherapy play a critical role.

With the development of precision medicine, treatment decisions increasingly rely on genetic testing and molecular profiling, allowing physicians to design more personalized treatment plans.

Common Colorectal Cancer Treatment Drugs in China (2026)

The following table summarizes several commonly used colorectal cancer drugs and their mechanisms of action.

Drug	Type	Mechanism	Common Use
Oxaliplatin	Chemotherapy	DNA cross-linking agent that inhibits tumor cell replication	Adjuvant therapy / first-line treatment
Irinotecan	Chemotherapy	Topoisomerase I inhibitor	Advanced colorectal cancer
Fluorouracil (5-FU)	Chemotherapy	Inhibits DNA synthesis	Core chemotherapy regimens
Capecitabine	Chemotherapy	Oral prodrug of 5-FU	Adjuvant treatment
Bevacizumab	Targeted therapy	Anti-VEGF monoclonal antibody	Metastatic colorectal cancer
Aflibercept	Targeted therapy	VEGF-trap fusion protein	Second-line therapy
Regorafenib	Targeted therapy	Multi-kinase inhibitor	Later-line treatment
Fruquintinib	Targeted therapy	VEGFR1/2/3 inhibitor	Metastatic colorectal cancer
Cetuximab	EGFR targeted therapy	EGFR monoclonal antibody	RAS wild-type patients
Panitumumab	EGFR targeted therapy	EGFR monoclonal antibody	Metastatic colorectal cancer
Pembrolizumab	Immunotherapy	PD-1 inhibitor	MSI-H / dMMR patients
Nivolumab	Immunotherapy	PD-1 inhibitor	MSI-H colorectal cancer
Ipilimumab	Immunotherapy	CTLA-4 inhibitor	Combined with nivolumab
Toripalimab	Immunotherapy	PD-1 monoclonal antibody	Investigational use in multiple cancers

🎯 This overview helps readers quickly understand the main colorectal cancer treatment drugs and mechanisms used in clinical practice.

Chemotherapy Drugs for Colorectal Cancer

Chemotherapy has long been one of the core colorectal cancer treatment options, particularly in postoperative adjuvant therapy and the management of advanced disease.

Common chemotherapy drugs include:

• Oxaliplatin
• Irinotecan
• Fluorouracil (5-FU)
• Capecitabine

These medications are typically used in combination regimens.

Two of the most widely used chemotherapy protocols include:

FOLFOX regimen

Oxaliplatin + Fluorouracil (5-FU) + Leucovorin

This regimen is commonly used for adjuvant therapy or first-line treatment in colorectal cancer.

FOLFIRI regimen

Irinotecan + Fluorouracil (5-FU) + Leucovorin

This combination is often used for advanced or metastatic colorectal cancer treatment.

Chemotherapy works by interfering with DNA replication and cell division in rapidly growing cancer cells. Although side effects may occur in some patients, advances in supportive care and dose management have significantly improved treatment safety.

Targeted Therapy for Colorectal Cancer

Targeted therapy represents a major advancement in modern colorectal cancer treatment options. These therapies work by specifically targeting molecular pathways involved in tumor growth and progression.

Compared with traditional chemotherapy, targeted therapies often provide more precise mechanisms of action and can improve outcomes for selected patient populations.

Anti-angiogenic (VEGF) Targeted Therapy

Tumor growth and metastasis depend on the formation of new blood vessels. Therefore, blocking angiogenesis has become an important therapeutic strategy.

Common VEGF-targeted drugs include:

• Bevacizumab
• Regorafenib
• Fruquintinib
• Aflibercept

Among them, Fruquintinib is an anti-angiogenic targeted therapy developed in China that inhibits the VEGFR signaling pathway. Clinical studies have shown its potential value in the treatment of metastatic colorectal cancer, and the drug has received regulatory approval in multiple countries.

EGFR Targeted Therapy

The epidermal growth factor receptor (EGFR) is another important molecular target in colorectal cancer.

For patients with RAS wild-type tumors, especially those with left-sided colorectal cancer, EGFR-targeted therapy may provide significant clinical benefits.

Common EGFR-targeted drugs include:

• Cetuximab
• Panitumumab

These therapies work by blocking EGFR signaling pathways and inhibiting tumor cell proliferation. Genetic testing is usually recommended before treatment to determine whether patients are suitable candidates for EGFR-targeted therapy.

Immunotherapy for Colorectal Cancer

Immunotherapy has become one of the most important colorectal cancer treatment options for certain patients in recent years. Immune checkpoint inhibitors activate the body’s immune system to recognize and attack cancer cells.

Currently, immunotherapy is mainly used for patients with:

• MSI-H (microsatellite instability-high)
• dMMR (deficient mismatch repair)

Key immunotherapy drugs include:

• Pembrolizumab
• Nivolumab
• Toripalimab
• Ipilimumab

Pembrolizumab and Nivolumab are widely used PD-1 immune checkpoint inhibitors that have demonstrated significant clinical benefits in multiple cancers, including colorectal cancer.

Meanwhile, Chinese-developed immunotherapy drugs such as Toripalimab are also being actively studied in clinical trials and are gradually entering the international oncology market.

Conclusion: Future Trends in Colorectal Cancer Treatment

With continuous advances in medical research, colorectal cancer treatment is gradually evolving from traditional chemotherapy toward targeted therapy, immunotherapy, and precision medicine.

Recently approved targeted therapies continue to expand colorectal cancer treatment options. For example, combination therapy including Encorafenib offers a new option for BRAF V600E–mutated metastatic colorectal cancer, according to the U.S. Food and Drug Administration. Readers interested in more cancer drug updates can explore our related oncology articles.👇

11 New Cancer Drugs Approved: Breakthroughs in Lung Cancer, Breast Cancer and Prostate Cancer Treatment

At the same time, stable pharmaceutical supply systems and global medical collaboration are helping improve access to anticancer medicines worldwide.

As part of the pharmaceutical supply chain, HongKong DengYueMed continues to monitor global developments in oncology therapies and is committed to promoting medical information exchange and international collaboration in innovative medicines.

Looking ahead, with further advances in biotechnology and precision medicine, colorectal cancer treatment is expected to achieve additional breakthroughs, bringing new hope to patients around the world.

FAQ about Colorectal Cancer Treatment Options